Want to see TSE:PCLO full AI Analyst Report?
PCLO Stock Chart & Stats
C$0.06
-C$0.01(-13.33%)
At close: 4:00 PM EDT
C$0.06
-C$0.01(-13.33%)
Day’s Range― - ―
52-Week RangeC$0.04 - C$0.17
Previous CloseN/A
Volume35.78K
Average Volume (3M)72.64K
Market Cap
C$10.28M
Enterprise ValueC$31.59M
Total Cash (Recent Filing)C$77.50K
Total Debt (Recent Filing)C$18.21M
Price to Earnings (P/E)―
Beta-3.88
Next Earnings
May 03, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.02
Shares Outstanding221,005,070
10 Day Avg. Volume146,144
30 Day Avg. Volume72,635
Financial Highlights & Ratios
PEG Ratio-0.01
Price to Book (P/B)-0.55
Price to Sales (P/S)3.24
P/FCF Ratio-8.30
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Revenue RecoveryThe strong TTM revenue rebound indicates improving commercial traction and product demand after weaker prior periods. If sustained, higher sales can provide operating leverage, support broader customer adoption, and create a foundation for the company to move closer to break-even.
Gross Margin ImprovementA materially higher gross margin suggests better pricing, product mix, and/or cost control in the underlying extract business. Maintaining this improvement would increase the contribution from each sale and make future revenue growth more valuable as the company works toward covering operating costs.
B2B Ingredient PlatformThe B2B model positions PharmaCielo as an ingredient supplier rather than relying only on consumer finished products. Serving medical, wellness, and pharmaceutical-related applications gives the platform several potential demand channels and allows customers to incorporate its extracts into their own products.
Bears Say
Persistent UnprofitabilityPersistent operating and net losses show that the business has not yet reached the scale needed to cover its cost base. Continued unprofitability can consume capital, limit reinvestment, and make the improved revenue and gross margin trends less durable until expenses are brought under control.
Negative Equity And Debt BurdenNegative equity combined with a sizable debt load leaves the company with limited financial flexibility and a weak capital base. This structure can increase refinancing and dilution risk, constrain investment in growth, and make recovery more dependent on stabilizing losses and rebuilding equity.
Negative Cash GenerationThe company is consuming cash rather than funding operations internally, so growth and ongoing obligations may require external financing. Persistently negative operating and free cash flow increases liquidity pressure and could limit strategic flexibility even if revenue and gross margin continue improving.
PharmaCielo News
PCLO FAQ
What was PharmaCielo’s price range in the past 12 months?
PharmaCielo lowest stock price was C$0.04 and its highest was C$0.17 in the past 12 months.
What is PharmaCielo’s market cap?
PharmaCielo’s market cap is C$10.28M.
When is PharmaCielo’s upcoming earnings report date?
PharmaCielo’s upcoming earnings report date is May 03, 2027 which is in 203 days.
How were PharmaCielo’s earnings last quarter?
PharmaCielo released its earnings results on Jul 29, 2026. The company reported -C$0.007 earnings per share for the quarter.
Is PharmaCielo overvalued?
According to Wall Street analysts PharmaCielo’s price is currently Overvalued.
Does PharmaCielo pay dividends?
PharmaCielo does not currently pay dividends.
What is PharmaCielo’s EPS estimate?
PharmaCielo’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does PharmaCielo have?
PharmaCielo has 221,005,070 shares outstanding.
What happened to PharmaCielo’s price movement after its last earnings report?
PharmaCielo reported an EPS of -C$0.007 in its last earnings report. Following the earnings report the stock price went down -4.762%.
Which hedge fund is a major shareholder of PharmaCielo?
Currently, no hedge funds are holding shares in TSE:PCLO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
PharmaCielo
PharmaCielo Ltd., operating in conjunction with its subsidiary, is primarily engaged in the comprehensive cultivation, processing, and distribution of pharmaceutical-grade cannabis extracts, including tetrahydrocannabinol (THC), and associated medicinal products. Additionally, the company diversifies its offerings by providing telemedicine software. Its clientele spans a range of entities, such as health and wellness product manufacturers, pharmacies, medical clinics, and cosmetic companies, across both Canada and Colombia. PharmaCielo also holds a strategic partnership with AssuredTrans Inc., and its corporate headquarters are situated in Toronto, Canada.
Technical Analysis
Willow Biosciences Inc
―
MediPharm Labs
―
Nextleaf Solutions
―
Avicanna
―
InnoCan Pharma
―